Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Atropine Sulfate,Scopolamine
Therapeutic Area : Pharmacology/Toxicology
Study Phase : IND Enabling
Sponsor : U.S. Defense Department
Deal Size : Undisclosed
Deal Type : Funding
Details : The funding will support the continued development of a promising medical countermeasure for nerve agents that contain a stable, fixed-dose combination formulation of atropine and scopolamine.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 06, 2022
Lead Product(s) : Atropine Sulfate,Scopolamine
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : IND Enabling
Sponsor : U.S. Defense Department
Deal Size : Undisclosed
Deal Type : Funding
LOOKING FOR A SUPPLIER?